FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rudolf Heijtink

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Procedures

Physiology

Pregnancy

Geographic Areas

Netherlands

Co-author Network

Publications

TOP 3
Jinlin Hou; Ralf Schilling; Harry L A Janssen; Bettina E Hansen; Rudolf Heijtink; Erwin Sablon; Roger Williams; George K K Lau; Solko W Schalm; Nikolai Naoumov
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
Annemiek A van der Eijk; Hubert G M Niesters; Bettina E Hansen; Rudolf Heijtink; Harry L A Janssen; Solko W Schalm; Robert A de Man
Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
Rudolf Heijtink; P M Schneeberger; B Postma; W Crombach
Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/l seroprotection levels unreliable.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rudolf Heijtink (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Jinlin Hou; Ralf Schilling; Harry L A Janssen; Bettina E Hansen; Rudolf Heijtink; Erwin Sablon; Roger Williams; George K K Lau; Solko W Schalm; Nikolai Naoumov
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
Journal of medical virology 2007;79(8):1055-63.
2006: Annemiek A van der Eijk; Hubert G M Niesters; Bettina E Hansen; Rudolf Heijtink; Harry L A Janssen; Solko W Schalm; Robert A de Man
Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
Journal of viral hepatitis 2006;13(2):96-103.
2002: Rudolf Heijtink; P M Schneeberger; B Postma; W Crombach
Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/l seroprotection levels unreliable.
Vaccine 2002;20(23-24):2899-905.
2002: Rudolf Heijtink; P van Bergen; K Melber; Z A Janowicz; A D M E Osterhaus
Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination.
Vaccine 2002;20(17-18):2191-6.
2002: Andeltje B van Nunen; Robert A de Man; Rudolf Heijtink; A C T M Vossen; Solko W Schalm
Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
Journal of viral hepatitis 2002;9(3):221-8.
2002: Rudolf Heijtink; J Kruining; PF van Bergen; S de Rave; Jan van Hattum; Martin Schutten; A D M E Osterhaus
Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine.
Journal of medical virology 2002;66(3):304-11.
2001: Rudolf Heijtink; Andeltje B van Nunen; PF van Bergen; L Ostberg; Albert D M E Osterhaus; Robert A de Man
Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes.
Journal of medical virology 2001;64(4):427-34.
2001: Rudolf Heijtink; PF van Bergen; MH van Roosmalen; CM Sünnen; WP Paulij; Solko W Schalm; Albert D M E Osterhaus
Anti-HBs after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines: binding to mutant HBsAg.
Vaccine 2001;19(27):3671-80.
2001: Rudolf Heijtink; Harry L A Janssen; Wim C J Hop; Albert D M E Osterhaus; Solko W Schalm
Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication.
Journal of medical virology 2001;63(3):217-9.
2000: Rudolf Heijtink; Harry L A Janssen; Wim C J Hop; Albert D M E Osterhaus; Solko W Schalm
Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy.
Journal of viral hepatitis 2000;7(5):382-6.
2000: Andeltje B van Nunen; Robert A de Man; Rudolf Heijtink; Hubert G M Niesters; Solko W Schalm
Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients.
Journal of hepatology 2000;32(6):1040-1.
2000: Rudolf Heijtink; PF van Bergen; WP Paulij; Robert A de Man; Albert D M E Osterhaus
Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines.
Vaccine 2000;18(15):1531-8.
1999: WP Paulij; P L de Wit; CM Sünnen; MH van Roosmalen; A Petersen-van Ettekoven; MP Cooreman; Rudolf Heijtink
Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen.
The Journal of general virology 1999;80 ( Pt 8)():2121-6.
1999: Harry L A Janssen; G Gerken; V Carreño; P Marcellin; Nikolai Naoumov; A Craxi; H Ring-Larsen; G Kitis; Jan van Hattum; Richard A de Vries; Peter P Michielsen; Fiebo J W Ten Kate; Wim C J Hop; Rudolf Heijtink; Pieter Honkoop; Solko W Schalm
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
Hepatology (Baltimore, Md.) 1999;30(1):238-43.
1999: Rudolf Heijtink; WP Paulij; PF van Bergen; MH van Roosmalen; D Rohm; B Eichentopf; E Muchmore; Robert A de Man; Albert D M E Osterhaus
In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee.
The Journal of general virology 1999;80 ( Pt 6)():1529-35.
1999: Rudolf Heijtink; WP Paulij; MH van Roosmalen; J A Hellings; Hubert G M Niesters; Solko W Schalm; Albert D M E Osterhaus
Characteristics of the early phase of chronicity in acute hepatitis B infection.
Journal of medical virology 1999;57(4):331-6.
1998: Johannes T Brouwer; Frederik Nevens; Bernhard Kleter; Ann Elewaut; Michael Adler; R Brenard; Robert Chamuleau; Peter P Michielsen; J Pirotte; ML Hautekeete; J Weber; Nadine Bourgeois; Bettina E Hansen; C M Bronkhorst; Fiebo J W Ten Kate; Rudolf Heijtink; J Fevery; Solko W Schalm
Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Journal of hepatology 1998;28(6):951-9.
1998: Bernhard Kleter; Johannes T Brouwer; Frederik Nevens; L J van Doorn; Ann Elewaut; J Versieck; Peter P Michielsen; ML Hautekeete; Robert Chamuleau; R Brénard; Nadine Bourgeois; M Adler; Wim Quint; C M Bronkhorst; Rudolf Heijtink; W J Hop; J Fevery; Solko W Schalm
Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C.
Liver 1998;18(1):32-8.
1997: Rudolf Heijtink; J Kruining; Pieter Honkoop; M C Kuhns; Wim C J Hop; Albert D M E Osterhaus; Solko W Schalm
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B.
Journal of medical virology 1997;53(3):282-7.
1997: R del Canho; P M Grosheide; J A Mazel; Rudolf Heijtink; W C Hop; L J Gerards; G C de Gast; Willem P F Fetter; J Zwijneberg; Solko W Schalm
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity.
Vaccine 1997;15(15):1624-30.
1997: Jan Balzarini; J Kruining; O Wedgwood; Christophe Pannecouque; Stefano Aquaro; Carlo Federico Perno; Lieve Naesens; Myriam Witvrouw; Rudolf Heijtink; Erik De Clercq; Christopher McGuigan
Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.
FEBS letters 1997;410(2-3):324-8.
1995: Robert A de Man; R P Sprey; Hubert G M Niesters; Rudolf Heijtink; P E Zondervan; W Hop; Solko W Schalm
Survival and complications in a cohort of patients with anti-delta positive liver disease presenting in a tertiary referral clinic.
Journal of hepatology 1995;23(6):662-7.
1995: P M Grosheide; J W Wladimiroff; Rudolf Heijtink; J A Mazel; G C Christiaens; A S Nuijten; Solko W Schalm
Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis.
BMJ (Clinical research ed.) 1995;311(7014):1197-9.
1995: Rudolf Heijtink; J Snobl; J Kruining; C Kerkhof-Los; Robert A de Man; H L Janssen; Solko W Schalm
Quantitative measurement of HBeAg in chronic hepatitis B: a comparison between a radioimmunoassay, a fluorescence ELISA and a chemiluminescence ELISA.
Journal of medical virology 1995;47(3):245-50.
1995: Pieter Honkoop; Robert A de Man; Rudolf Heijtink; Solko W Schalm
Hepatitis B reactivation after lamivudine.
Lancet 1995;346(8983):1156-7.
1995: Rudolf Heijtink; J Kruining; Y A Weber; Robert A de Man; Solko W Schalm
Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an "inhibition in solution" assay.
Hepatology (Baltimore, Md.) 1995;22(4 Pt 1):1078-83.
1995: G E Kleter; Leen-Jan van Doorn; Lieven Stuyver; Geert Maertens; Johannes T Brouwer; Solko W Schalm; Rudolf Heijtink; Wim Quint
Rapid genotyping of hepatitis C virus RNA-isolates obtained from patients residing in western Europe.
Journal of medical virology 1995;47(1):35-42.
1995: Leen-Jan van Doorn; G E Kleter; Lieven Stuyver; Geert Maertens; Johannes T Brouwer; Solko W Schalm; Rudolf Heijtink; Wim Quint
Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries.
The Journal of general virology 1995;76 ( Pt 7)():1871-6.
1995: J Kruining; Rudolf Heijtink; Solko W Schalm
Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment.
Journal of hepatology 1995;22(3):263-7.
1995: Wim Quint; Rudolf Heijtink; J Schirm; W H Gerlich; H G Niesters
Reliability of methods for hepatitis B virus DNA detection.
Journal of clinical microbiology 1995;33(1):225-8.
1995: Solko W Schalm; Robert A de Man; Rudolf Heijtink; Hubert G M Niesters
New nucleoside analogues for chronic hepatitis B.
Journal of hepatology 1995;22(1 Suppl):52-6.
1994: R del Canho; P M Grosheide; M Voogd-Schotanus; W M Huisman; Rudolf Heijtink; Solko W Schalm
Immunogenicity of two different dosages (10 and 5 micrograms) of recombinant DNA hepatitis B vaccine in healthy neonates.
Vaccine 1994;12(14):1323-6.
1994: P M Grosheide; R del Canho; M Voogd; Rudolf Heijtink; Solko W Schalm
Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Dutch Study Group on Prevention of Neonatal Hepatitis B.
Vaccine 1994;12(12):1059-63.
1994: Rudolf Heijtink; J Kruining; G A de Wilde; J Balzarini; E de Clercq; Solko W Schalm
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture.
Antimicrobial agents and chemotherapy 1994;38(9):2180-2.
1994: P M Grosheide; H W Quartero; Solko W Schalm; Rudolf Heijtink; G C Christiaens
Early invasive prenatal diagnosis in HBsAg-positive women.
Prenatal diagnosis 1994;14(7):553-8.
1994: Leen-Jan van Doorn; Bernhard Kleter; Lieven Stuyver; Geert Maertens; H Brouwer; Solko W Schalm; Rudolf Heijtink; Wim Quint
Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles.
Journal of hepatology 1994;21(1):122-9.
1994: S de Rave; Rudolf Heijtink; M Bakker-Bendik; J Boot; Solko W Schalm
Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers.
Vaccine 1994;12(6):532-4.
1994: R del Canho; P M Grosheide; Solko W Schalm; R R de Vries; Rudolf Heijtink
Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates.
Journal of hepatology 1994;20(4):483-6.
1994: H L Janssen; C J Kerhof-Los; Rudolf Heijtink; Solko W Schalm
Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy.
Antiviral research 1994;23(3-4):251-7.
1994: Wim Quint; Willem P F Fetter; H C van Os; Rudolf Heijtink
Absence of hepatitis B virus (HBV) DNA in children born after exposure of their mothers to HBV during in vitro fertilization.
Journal of clinical microbiology 1994;32(4):1099-100.
1994: G E Kleter; Leen-Jan van Doorn; Johannes T Brouwer; Solko W Schalm; Rudolf Heijtink; Wim Quint
Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands.
Journal of clinical microbiology 1994;32(2):306-10.
1994: Leen-Jan van Doorn; Bernhard Kleter; J Voermans; Geert Maertens; H Brouwer; Rudolf Heijtink; Wim Quint
Rapid detection of hepatitis C virus RNA by direct capture from blood.
Journal of medical virology 1994;42(1):22-8.
1993: R del Canho; P M Grosheide; Rudolf Heijtink; Solko W Schalm
[The course of hepatitis B in 9 children who became positive for viral surface antigen HBsAg in spite of vaccination].
Nederlands tijdschrift voor geneeskunde 1993;137(50):2599-603.
1993: P M Grosheide; R del Canho; Rudolf Heijtink; A S Nuijten; J Zwijnenberg; J R Bänffer; Y W Wladimiroff; M J Botman; J A Mazel; G C de Gast
Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization.
American journal of diseases of children (1960) 1993;147(12):1316-20.
1993: R del Canho; P M Grosheide; M Voogd; W M Huisman; Rudolf Heijtink; Solko W Schalm
Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes.
Journal of medical virology 1993;41(1):30-4.
1993: Robert A de Man; H J Metselaar; Rudolf Heijtink; Solko W Schalm
Long-term application of human polyclonal hepatitis-B immunoglobulin to prevent hepatic allograft infection. A review of the literature and presentation of five cases.
The Netherlands journal of medicine 1993;43(1-2):74-82.
1993: H L Janssen; Y A Schoenmaker-Weber; H Kruining; Solko W Schalm; Rudolf Heijtink
Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B: comparison of two solution hybridization assays.
Journal of medical virology 1993;40(4):307-12.
1993: P M Grosheide; Solko W Schalm; H C van Os; Willem P F Fetter; Rudolf Heijtink
Immune response to hepatitis B vaccine in pregnant women receiving post-exposure prophylaxis.
European journal of obstetrics, gynecology, and reproductive biology 1993;50(1):53-8.
1993: G A de Wilde; Rudolf Heijtink
Immuno disc assay for screening duck hepatitis B surface antigen in serum, liver tissue and cultured hepatocytes.
Journal of virological methods 1993;43(1):41-51.
1993: Rudolf Heijtink; G A De Wilde; J Kruining; L Berk; J Balzarini; E De Clercq; A Holy; Solko W Schalm
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection.
Antiviral research 1993;21(2):141-53.
1993: L Jabaaij; P M Grosheide; Rudolf Heijtink; H J Duivenvoorden; Rudy E Ballieux; Ad J J M Vingerhoets
Influence of perceived psychological stress and distress on antibody response to low dose rDNA hepatitis B vaccine.
Journal of psychosomatic research 1993;37(4):361-9.
1993: R del Canho; P M Grosheide; L J Gerards; Rudolf Heijtink; Solko W Schalm
Hepatitis B vaccination and preterm infants.
The Pediatric infectious disease journal 1993;12(5):407-8.
1993: H L Janssen; L Berk; Rudolf Heijtink; Fiebo J W Ten Kate; Solko W Schalm
Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial.
Hepatology (Baltimore, Md.) 1993;17(3):383-8.
1993: G E Kleter; Johannes T Brouwer; Rudolf Heijtink; Solko W Schalm; Wim Quint
Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon.
Antimicrobial agents and chemotherapy 1993;37(3):595-7.
1993: H L Janssen; Solko W Schalm; L Berk; Robert A de Man; Rudolf Heijtink
Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.
Journal of hepatology 1993;17 Suppl 3():S47-51.
1992: L Berk; Solko W Schalm; Rudolf Heijtink
Zidovudine inhibits hepatitis B virus replication.
Antiviral research 1992;19(2):111-8.
1992: R Del Canho; P M Grosheide; L J Gerards; Rudolf Heijtink; Solko W Schalm
[Premature infants and hepatitis B vaccination. Study Group Prevention Neonatal Hepatitis B].
Tijdschrift voor kindergeneeskunde 1992;60(4):105-11.
1992: H L Janssen; L Berk; Solko W Schalm; Rudolf Heijtink; G Hess; S Rossol; K H Meyer zum Buschenfelde; Robert Chamuleau; P L Jansen; H W Reesink
Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.
Gut 1992;33(8):1094-8.
1992: H L Janssen; L Berk; Robert A de Man; Rudolf Heijtink; Solko W Schalm
[Alpha-interferon antiviral treatment in 100 patients with chronic hepatitis B].
Nederlands tijdschrift voor geneeskunde 1992;136(17):835-9.
1992: F J ten Kate; Solko W Schalm; P J Willemse; A P Blok; Rudolf Heijtink; Onno T Terpstra
Course of hepatitis B and D virus infection in auxiliary liver grafts in hepatitis B-positive patients. A light-microscopic and immunohistochemical study.
Journal of hepatology 1992;14(2-3):168-75.
1992: R del Canho; Solko W Schalm; Rudolf Heijtink
Hepatitis B revaccination of neonates with inadequate response after primovaccination.
Vaccine 1992;10(1):69.
1991: L Berk; Solko W Schalm; Rudolf Heijtink
Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses.
Gut 1991;32(10):1198-200.
1991: A C Kroes; Wim Quint; Rudolf Heijtink
Significance of isolated hepatitis B core antibodies detected by enzyme immunoassay in a high risk population.
Journal of medical virology 1991;35(2):96-100.
1991: P M Grosheide; H C van Osand; Solko W Schalm; Rudolf Heijtink
Immunoprophylaxis to limit a hepatitis B epidemic among women undergoing in vitro fertilization.
Vaccine 1991;9(9):682-7.
1991: H C van Os; A C Drogendijk; Willem P F Fetter; Rudolf Heijtink; G H Zeilmaker
The influence of contamination of culture medium with hepatitis B virus on the outcome of in vitro fertilization pregnancies.
American journal of obstetrics and gynecology 1991;165(1):152-9.
1991: L Berk; Robert A de Man; Solko W Schalm; R P Labadie; Rudolf Heijtink
Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed.
Journal of hepatology 1991;12(3):405-6.
1990: W G Quint; I de Bruijn; H Kruining; Rudolf Heijtink
HBV-DNA detection by gene amplification in acute hepatitis B.
Hepatology (Baltimore, Md.) 1990;12(4 Pt 1):653-6.
1990: M B Smit-Leijs; P Kramer; Rudolf Heijtink; W C Hop; Solko W Schalm
Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma-derived vaccine with and without pre-S2 antigen.
European journal of clinical investigation 1990;20(5):540-5.
1989: P J Boender; Rudolf Heijtink; J A Hellings
Nucleosomal fragments in serum may directly reflect cell-mediated cytotoxic activity in vivo.
Clinical immunology and immunopathology 1989;53(1):87-98.
1989: Rudolf Heijtink; G A de Wilde; J Kruining; M B Smit-Leijs; Solko W Schalm
Anti-pre-S(2) analysis after hepatitis B vaccination in haemodialysis patients.
Antiviral research 1989;12(2):75-86.
1989: Solko W Schalm; J A Mazel; G C de Gast; Rudolf Heijtink; M J Botman; J R Bänffer; L J Cerards; J Zwijnenberg; Willem P F Fetter; S M Nuijten
Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen.
Pediatrics 1989;83(6):1041-8.
1989: Robert A de Man; Solko W Schalm; A J van der Heijden; F W ten Kate; E D Wolff; Rudolf Heijtink
Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy.
Journal of hepatology 1989;8(3):367-72.
1989: Rudolf Heijtink; G A de Wilde; J van Hattum; Solko W Schalm
Long-term immune reactivity to pre-S(2)-antigen after acute hepatitis B infection.
Journal of medical virology 1989;27(2):95-9.
1989: Rudolf Heijtink; R M Knol; Solko W Schalm
Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes.
Journal of medical virology 1989;27(2):151-4.
1989: A T Alberda; H C van Os; G H Zeilmaker; P H Rothbarth; Rudolf Heijtink; Solko W Schalm
[Hepatitis B virus infection in women treated with in-vitro fertilization].
Nederlands tijdschrift voor geneeskunde 1989;133(1):20-5.
1988: J Kruining; P G Mulder; Rudolf Heijtink
Immune response to HBsAg differently interpreted by RIA and EIA.
Journal of virological methods 1988;22(1):89-98.
1988: Robert A de Man; Solko W Schalm; Rudolf Heijtink; L Berk; J Den Ouden; F J ten Kate; Robert Chamuleau; H W Reesink
Long-term follow-up of antiviral combination therapy in chronic hepatitis B.
The American journal of medicine 1988;85(2A):150-4.
1988: Rudolf Heijtink; Y A Weber; J A Mazel
Hepatitis B vaccination in newborn babies.
Lancet 1988;1(8596):1226.
1988: Rudolf Heijtink; A A Breukers; G den Hartigh; R W Schepman; P I Schmitz; Solko W Schalm; N Masurel
Low dose intradermal vaccination against hepatitis B in mentally retarded patients.
Vaccine 1988;6(1):59-61.
1987: Rudolf Heijtink; P Smal; F J ten Kate; J Kruining; Solko W Schalm
Detection of HBV-DNA in liver biopsy and serum: its significance in the selection of hepatitis B patients for antiviral therapy.
Antiviral research 1987;7(6):329-40.
1987: Rudolf Heijtink; Solko W Schalm; J Kruining; M J Tyrrell-Heijgen; P Bakker; J Boot; P I Schmitz; N Masurel
Hepatitis B vaccination in health care workers: assessment of simple guidelines.
The Netherlands journal of medicine 1987;30(3-4):117-27.
1985: P J Boender; S W Schalm; Rudolf Heijtink
Detection of integration during active replication of hepatitis B virus in the liver.
Journal of medical virology 1985;16(1):47-54.
1985: Rudolf Heijtink; J Kruining; Solko W Schalm; N Masurel
Comparison of two techniques for detecting antibody to HBsAg during a hepatitis B vaccine study.
Journal of virological methods 1985;10(4):333-9.
1985: J A Mazel; Rudolf Heijtink; Solko W Schalm; L J Gerards; M J Botman; J R Bänffer; G C de Gast; A S Nuyten; J W Wladimiroff; J Zwijnenberg
[Combined passive and active immunization of infants of HbsAg-positive mothers].
Nederlands tijdschrift voor geneeskunde 1985;129(13):590-4.
1985: Rudolf Heijtink; J Kruining; M Bakker; Solko W Schalm
Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma-derived vaccine.
Antiviral research 1985;Suppl 1():273-9.
1984: J A Mazel; Solko W Schalm; B C de Gast; A S Nuijten; Rudolf Heijtink; M J Botman; J R Bänffer; L J Gerards; J Zwijnenberg; J Mettau
Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations.
British medical journal (Clinical research ed.) 1984;288(6416):513-5.
1983: Rudolf Heijtink; J Kruining; Solko W Schalm; N Masurel
Hepatitis B: prevaccination screening of individuals simultaneously positive for HBsAg and anti-HBs in one assay.
Lancet 1983;1(8332):1050-1.
1983: J de Vries; J Kruining; Rudolf Heijtink
Evaluation of a semi-automatic radioimmunoassay for hepatitis B surface antigen (HBsAg).
Journal of virological methods 1983;6(2):107-15.